Galena Biopharma (NASDAQ:GALE) was downgraded by Cantor Fitzgerald from a “buy” rating to a “sell” rating in a research note issued on Tuesday, TheFlyOnTheWall.com reports. They currently have a $3.50 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential downside of 6.17% from the stock’s previous close. Galena Biopharma Inc (NASDAQ:GALE) stock opened at $3.47 in last trading session, and closed at $3.79, trading in the range of $3.26 – $3.93. The stock showed a negative weekly performance of -29.68%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) average recommendation is buy with average Target Price of $5.50. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares closed at $4.78 on last trade day, by gaining 8.64%. Stock 52 week range is $0.19 – $5.55. Company’s market capitalization is $304.44 billion.
Piper Jaffray set a $45.00 price target on shares of Insmed (NASDAQ:INSM) stock in a research note issued on Tuesday, Analyst Ratings Network.com reports. Piper Jaffray’s target price indicates a potential upside of 170.92% from the stock’s previous close. Insmed Incorporated (NASDAQ:INSM) stock advanced 9.45% and finished the last session at $18.18. The EPS of the stock remained -1.67. Company’s market capitalization is $711.02 billion.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) said Tuesday that the U.S. Food and Drug Administration granted accelerated approval of Northera, its treatment of symptomatic neurogenic orthostatic hypotension. Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops products for the treatment of a variety of human diseases, including central nervous system disorders. The accelerated approval mechanism is aimed at speeding drugs to market. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock opened at $5.06 in last trading session and closed at $4.95. The 52 week range of the stock is $0.76 – $5.78 and the day range was $4.80 – $5.30.